The pharmacoeconomic evaluation exemption system is receiving much scrutiny. Under the pretense of improving the system, there are growing voices in favor of reducing of the system, supporting its reduced and limited application.

These discussions reached culmination in a session titled, ‘On improving the pharmacoeconomic evaluation exemption system’ held during a symposium by the Korean Association of Health Technology Assessment (KAHTA).

At the symposium, Professor Sojeong Hwang from the Seoul National University Graduate School of Public Health gave a presentation titled 'Research on the improvement of the cost-effectiveness evaluation waiver system for drugs (current status and ev